Growth Hormone Deficiency in Children
Conditions
Brief summary
The purpose of the study is to investigate the safety and effectiveness of Sogroya® in children with short stature due to growth hormone deficiency where epiphysial discs are not closed under real-world clinical practice in Japan. The study will last for about 1 year (at shortest) to 3 years (at longest) depending on when the participant takes part in the study. The participant will be asked to answer questionnaire(s) about how they feel about the growth hormone (GH) product treatment once during the study (at about 3 months after starting the Sogroya® treatment) and about 3 months after starting the Sogroya® treatment.
Interventions
DRUGSomapacitan
Sogroya® treatment regimen will be in accordance with the approved product labelling in Japan.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. The decision to initiate treatment with commercially available Sogroya® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study. Both GH treatment naïve and non-naïve children are eligible. 3. Male or female age 0 to 18 years (exclusive) at the time of signing informed consent. 4. Diagnosis with short stature due to GHD where epiphysial discs are not closed according to local normal clinical practice.
Exclusion criteria
1. Previous participation in this study. Participation is defined as having given informed consent in this study. 2. Treatment with any investigational drug within 30 days prior to baseline (the starting date of Sogroya® treatment). 3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. 4. Contraindication described in approved product labelling in Japan. 1. Patients with hypersensitivity to the active substance or to any of the excipients 2. Patients with malignant tumour 3. Female patients who are either pregnant or likely to be pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of adverse reactions (AR) | From baseline (week 0) to end of study (up to 156 weeks) | Measured as count of reactions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of adverse events (AEs) | From baseline (week 0) to end of study (up to 156 weeks) | Measured as count of events. |
| Number of serious adverse events (SAEs) | From baseline (week 0) to end of study (up to 156 weeks) | Measured as count of events. |
| Number of serious adverse reactions (SARs) | From baseline (week 0) to end of study (up to 156 weeks) | Measured as count of reactions. |
| Change in height velocity (HV) | Every 12 months from baseline (week 0) to end of study (up to 156 weeks) | Measured in centimeter (cm)/year. |
| Change in bone age | Every 12 months from baseline (week 0) to end of study (up to 156 weeks) | Measured in years. |
| Change in ratio of bone age/chronological age | Every 12 months from baseline (week 0) to end of study (up to 156 weeks) | — |
| Change in height standard deviation score (HSDS) | Every 12 months from baseline (week 0) to end of study (up to 156 weeks) | — |
| Change in height velocity standard deviation score (HVSDS) | Every 12 months from baseline (week 0) to end of study (up to 156 weeks) | — |
| Change in insulin-like growth factor-I standard deviation score (IGF-I SDS) | Every 12 months from baseline (week 0) to end of study (up to 156 weeks) | Measured as score ranging from -10 to +10. Negative scores indicated a IGF-I below the mean IGF-I for a child with the same age and gender, whereas positive scores indicated a IGF-I above the mean IGF-I for a child with the same age and gender. For participants with low IGF-I SDS at baseline, a positive change from baseline in IGF-I SDS indicated a better outcome. |
| Growth hormone device assessment tool (G-DAT) | At 12 weeks | Measured as count of patients choosing the individual response category. G-DAT is a questionnaire to gather information on how they feel about the GH product device assessed as "very easy", "easy", "neither difficult or easy", "difficult" or "very difficult" where "very easy" is best and "very difficult" is worst. |
| Growth hormone patient preference questionnaire (GH-PPQ) | At 12 weeks | Measured as count of patients choosing the individual response category. GH-PPQ is a disease specific questionnaire which measures the patient's growth hormone treatment preference. |
Countries
Japan
Contacts
STUDY_DIRECTORClinical Transparency dept. 2834
Novo Nordisk A/S
Outcome results
None listed